D. E. Shaw & Co. Inc. Boosts Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

D. E. Shaw & Co. Inc. increased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 37.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 315,263 shares of the biotechnology company's stock after acquiring an additional 86,173 shares during the period. D. E. Shaw & Co. Inc. owned approximately 0.15% of BioCryst Pharmaceuticals worth $2,371,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. KBC Group NV grew its position in shares of BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after acquiring an additional 4,537 shares during the period. R Squared Ltd purchased a new position in BioCryst Pharmaceuticals in the 4th quarter valued at about $48,000. China Universal Asset Management Co. Ltd. lifted its stake in BioCryst Pharmaceuticals by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 43,920 shares of the biotechnology company's stock valued at $330,000 after buying an additional 4,129 shares in the last quarter. Choreo LLC purchased a new position in BioCryst Pharmaceuticals in the 4th quarter worth approximately $106,000. Finally, Rhumbline Advisers lifted its stake in BioCryst Pharmaceuticals by 1.8% in the 4th quarter. Rhumbline Advisers now owns 309,132 shares of the biotechnology company's stock worth $2,325,000 after purchasing an additional 5,615 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Up 1.9%

NASDAQ BCRX traded up $0.20 on Friday, hitting $10.59. The stock had a trading volume of 3,608,168 shares, compared to its average volume of 3,022,861. BioCryst Pharmaceuticals, Inc. has a one year low of $5.92 and a one year high of $11.11. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of -17.36 and a beta of 1.08. The company's 50-day moving average is $8.38 and its two-hundred day moving average is $8.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analysts' expectations of $126.64 million. During the same period last year, the firm earned $0.28 EPS. The business's quarterly revenue was up 40.8% compared to the same quarter last year. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on BCRX shares. Barclays raised their target price on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday. Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price target on the stock. Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price target on the stock. Finally, JPMorgan Chase & Co. lifted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $16.56.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.